Orexigen “Open To Any Type Of Transaction” After Contrave Approval
As essentially a single-asset company, Orexigen hopes to use revenue from its pending obesity product to add other assets.
You may also be interested in...
Next PrecisionFDA challenge aims to detect ‘adverse event anomalies’ including manufacturer-specific patterns and drug-drug interactions.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Stephen Hahn will go before the Senate health committee less than three weeks after being nominated. Pink Sheet's historical charts illustrate how a long wait and a quick hearing could mean a rapid confirmation.